Fate Therapeutics upgraded by Piper Sandler with a new price target
$FATE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Piper Sandler upgraded Fate Therapeutics from Neutral to Overweight and set a new price target of $6.00 from $4.00 previously